Comment on "Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial"

被引:0
|
作者
Ferreira, Daniel
机构
关键词
EARLY DISCHARGE; SEVERITY INDEX;
D O I
10.1016/j.repc.2012.01.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Although practice guidelines recommend outpatient care for selected, haemodynamically stable patients with pulmonary embolism, most treatment is presently inpatient based. We aimed to assess non-inferiority of outpatient care compared with inpatient care. Methods: We undertook an open-label, randomised non-inferiority trial at 19 emergency departments in Switzerland, France, Belgium, and the USA. We randomly assigned patients with acute, symptomatic pulmonary embolism and a low risk of death (pulmonary embolism severity index risk classes I or II) with a computer-generated randomisation sequence (blocks of 2-4) in a 1:1 ratio to initial outpatient (ie, discharged from hospital <= 24 h after randomisation) or inpatient treatment with subcutaneous enoxaparin (>= 5 days) followed by oral anticoagulation (>= 90 days). The primary outcome was symptomatic, recurrent venous thromboembolism within 90 days; safety outcomes included major bleeding within 14 or 90 days and mortality within 90 days. We used a non-inferiority margin of 4% for a difference between inpatient and outpatient groups. We included all enrolled patients in the primary analysis, excluding those lost to follow-up. This trial is registered with ClinicalTrials.gov, number NCT00425542. Findings: Between February, 2007, and June, 2010, we enrolled 344 eligible patients. In the primary analysis, one (0.6%) of 171 outpatients developed recurrent venous thromboembolism within 90 days compared with none of 168 inpatients (95% upper confidence limit [UCL] 2.7%; p = 0.011). Only one (0.6%) patient in each treatment group died within 90 days (95% UCL 2.1%; p = 0.005), and two (1.2%) of 171 outpatients and no inpatients had major bleeding within 14 days (95% UCL 3.6%; p = 0.031). By 90 days, three (1.8%) outpatients but no inpatients had developed major bleeding (95% UCL 4.5%; p = 0.086). Mean length of stay was 0.5 days (SD 1.0) for outpatients and 3.9 days (SD 3.1) for inpatients. Interpretation: In selected low-risk patients with pulmonary embolism, outpatient care can safely and effectively be used in place of inpatient care.
引用
收藏
页码:263 / 264
页数:2
相关论文
共 50 条
  • [21] Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label blinded-outcome, randomised non-inferiority trial
    Fischer, Urs
    Kaesmacher, Johannes
    Strbian, Daniel
    Eker, Omer
    Cognard, Christoph
    Plattner, Patricia S.
    Butikofer, Lukas
    Mordasini, Pasquale
    Deppeler, Sandro
    Pereira, Vitor M.
    Albucher, Jean Francois
    Darcourt, Jean
    Bourcier, Romain
    Benoit, Guillon
    Papagiannaki, Chrysanthi
    Ozkul-Wermester, Ozlem
    Sibolt, Gerli
    Tiainen, Marjaana
    Gory, Benjamin
    Richard, Sebastien
    Liman, Jan
    Ernst, Marielle Sophie
    Boulanger, Marion
    Barbier, Charlotte
    Mechtouff, Laura
    Zhang, Liqun
    Marnat, Gaultier
    Sibon, Igor
    Nikoubashman, Omid
    Reich, Arno
    Consoli, Arturo
    Lapergue, Bertrand
    Ribo, Marc
    Tomasello, Alejandro
    Saleme, Suzana
    Macian, Francisco
    Moulin, Solne
    Pagano, Paolo
    Saliou, Guillaume
    Carrera, Emmanuel
    Janot, Kevin
    Hernandez-Perez, Maria
    Pop, Raoul
    Della Schiava, Lucie
    Luft, Andreas R.
    Piotin, Michel
    Gentric, Jean Christophe
    Pikula, Aleksandra
    Pfeilschifter, Waltraud
    Arnold, Marcel
    LANCET, 2022, 400 (10346): : 104 - 115
  • [22] Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial
    Diletti, Roberto
    den Dekker, Wijnand K.
    Bennett, Johan
    Schotborgh, Carl E.
    van der Schaaf, Rene
    Sabate, Manel
    Moreno, Raul
    Ameloot, Koen
    van Bommel, Rutger
    Forlani, Daniele
    van Reet, Bert
    Esposito, Giovanni
    Dirksen, Maurits T.
    Ruifrok, Willem P. T.
    Everaert, Bert R. C.
    Van Mieghem, Carlos
    Elscot, Jacob J.
    Cummins, Paul
    Lenzen, Mattie
    Brugaletta, Salvatore
    Boersma, Eric
    Van Mieghem, Nicolas M.
    LANCET, 2023, 401 (10383): : 1172 - 1182
  • [23] Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial
    Deterding, Katja
    Gruner, Norbert
    Buggisch, Peter
    Wiegand, Johannes
    Gale, Peter R.
    Spengler, Ulrich
    Hinrichsen, Holger
    Berg, Thomas
    Potthoff, Andrej
    Malek, Nisar
    Groshennig, Anika
    Koch, Armin
    Diepolder, Helmut
    Luth, Stefan
    Feyerabend, Sandra
    Jung, Maria Christina
    Rogalska-Taranta, Magdalena
    Schlaphoff, Verena
    Comberg, Markus
    Manns, Michael P.
    Wedemeyer, Heiner
    LANCET INFECTIOUS DISEASES, 2013, 13 (06): : 497 - 506
  • [24] Comment on Miki et al.: Randomized open-label non-inferiority trial of acetaminophen or loxoprofen for patients with acute low back pain
    Toda, Katsuhiro
    JOURNAL OF ORTHOPAEDIC SCIENCE, 2019, 24 (01) : 189 - 189
  • [25] Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
    Drucker, Daniel J.
    Buse, John B.
    Taylor, Kristin
    Kendall, David M.
    Trautmann, Michael
    Zhuang, Dangliang
    Porter, Lisa
    LANCET, 2008, 372 (9645): : 1240 - 1250
  • [26] Single-dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: an open-label, non-inferiority, randomised trial
    Mitja, Oriol
    Hays, Russell
    Ipai, Anthony
    Penias, Moses
    Paru, Raymond
    Fagaho, David
    de Lazzari, Elisa
    Bassat, Quique
    LANCET, 2012, 379 (9813): : 342 - 347
  • [27] Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial
    Porter, Duncan
    van Melckebeke, Jurgen
    Dale, James
    Messow, C. Martina
    McConnachie, Alexander
    Walker, Andrew
    Munro, Robin
    McLaren, John
    McRorie, Euan
    Packham, Jon
    Buckley, Christopher D.
    Harvie, John
    Taylor, Peter
    Choy, Ernest
    Pitzalis, Costantino
    McInnes, Iain B.
    LANCET, 2016, 388 (10041): : 239 - 247
  • [28] Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial
    de Jonge, Nick A.
    Sikkens, Jonne J.
    Zweegman, Sonja
    Beeker, Aart
    Ypma, Paula
    Herbers, Alexandra H.
    Vasmel, Wies
    de Kreuk, Arne
    Coenen, Juleon L. L. M.
    Lissenberg-Witte, Birgit
    Kramer, Mark H. H.
    van Agtmael, Michiel A.
    Janssen, Jeroen J. W. M.
    LANCET HAEMATOLOGY, 2022, 9 (08): : E563 - E572
  • [29] Outpatient versus inpatient uterine polyp treatment for abnormal uterine bleeding: randomised controlled non-inferiority study
    Cooper, Natalie A. M.
    Clark, T. Justin
    Middleton, Lee
    Diwakar, Lavanya
    Smith, Paul
    Denny, Elaine
    Roberts, Tracy
    Stobert, Lynda
    Jowett, Susan
    Daniels, Jane
    BMJ-BRITISH MEDICAL JOURNAL, 2015, 350
  • [30] Outpatient elective induction of labour at 39 weeks' gestation (HOME INDUCTION): an open-label, randomised, controlled, phase III, non-inferiority trial
    Nicholson, Sarah M.
    Flood, Karen
    Dicker, Patrick
    Molphy, Zara E.
    Smith, Orla T.
    Oprescu, Corina I.
    Wall, Eimear M.
    Nimr, Sara N. El
    Shanahan, Ita M.
    Kennedy, Bernard J.
    V. Daly, Ronan
    Gannon, Geraldine
    Looi, Claudia
    Fernandez, Elena
    Malone, Fergal D.
    ECLINICALMEDICINE, 2024, 74